RE: Wooly2 Feb 2021 07:23
RNS & Investor News
Proposed Director appointment
02 February 2021
Directorate change
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that it intends to appoint Stephen Hammond MP, as a Non- Executive Director of the Company, subject to the completion of regulatory due diligence being carried out by the Company's Nomad.
Stephen has been a Member of Parliament since 2005, fulfilling roles as Parliamentary Under Secretary of State for Transport from 2012 to 2014 and more recently Minister of State for the Department of Health and Social Care from 2018 to 2019.
Prior to his role in politics, Stephen had a successful career in finance at a leading fund management house and at a number of major European investment banks. He was a Director of the Equities division of Dresdner Kleinwort Benson from 1994 to 1998, a private bank providing financial services to high net worth individuals and corporate clients in the UK. After this he joined Commerzbank Securities, a leading international commercial bank described as 'Germany's Leading Brokerage Firm' of the past 10 years (https://tinyurl.com/y5re88mg), with branches and offices in nearly 50 countries. He was with Commerzbank Securities from 1998 until 2003. During this time, Stephen was promoted to Director in Pan European Research, with the responsibility for 70 professionals based in London and across Europe, before becoming an MP in 2005.
A further announcement will be made in due course.
Neil Davidson, Chairman of OptiBiotix commented: "Stephen's appointment reflects the continued evolution and ambition of the Board as the Company moves into the next phase of its development in becoming a profitable international business with global brands. Stephen's international understanding of healthcare, finance and experience of working in senior positions within finance and government complements the current Board's wealth of experience.
"The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products."